304 related articles for article (PubMed ID: 26626718)
21. Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline.
Zinner SH; Gilbert D; Lubenko IY; Greer K; Firsov AA
J Antimicrob Chemother; 2008 Mar; 61(3):629-35. PubMed ID: 18245198
[TBL] [Abstract][Full Text] [Related]
22. Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model.
Alieva KN; Golikova MV; Portnoy YA; Dovzhenko SA; Kobrin MB; Zinner SH; Firsov AA
J Chemother; 2018; 30(6-8):364-370. PubMed ID: 30663551
[TBL] [Abstract][Full Text] [Related]
23. Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.
Firsov AA; Gilbert D; Greer K; Portnoy YA; Zinner SH
Antimicrob Agents Chemother; 2012 Mar; 56(3):1223-8. PubMed ID: 22203591
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the minimum inhibitory, mutant prevention and minimum bactericidal concentrations of ciprofloxacin, levofloxacin and garenoxacin against enteric Gram-negative urinary tract infection pathogens.
Hansen GT; Blondeau JM
J Chemother; 2005 Oct; 17(5):484-92. PubMed ID: 16323436
[TBL] [Abstract][Full Text] [Related]
25. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Hansen GT; Zhao X; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
[TBL] [Abstract][Full Text] [Related]
26. Are ciprofloxacin dosage regimens adequate for antimicrobial efficacy and prevention of resistance? Pseudomonas aeruginosa bloodstream infection in elderly patients as a simulation case study.
Cazaubon Y; Bourguignon L; Goutelle S; Martin O; Maire P; Ducher M
Fundam Clin Pharmacol; 2015 Dec; 29(6):615-24. PubMed ID: 26406268
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar.
Hyatt JM; Nix DE; Schentag JJ
Antimicrob Agents Chemother; 1994 Dec; 38(12):2730-7. PubMed ID: 7695254
[TBL] [Abstract][Full Text] [Related]
28. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
Linde HJ; Lehn N
J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
[TBL] [Abstract][Full Text] [Related]
29. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
[TBL] [Abstract][Full Text] [Related]
30. Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model.
Madaras-Kelly KJ; Ostergaard BE; Hovde LB; Rotschafer JC
Antimicrob Agents Chemother; 1996 Mar; 40(3):627-32. PubMed ID: 8851583
[TBL] [Abstract][Full Text] [Related]
31. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.
Lubenko IY; Strukova EV; Smirnova MV; Vostrov SN; Portnoy YA; Zinner SH; Firsov AA
J Antimicrob Chemother; 2008 Nov; 62(5):1065-9. PubMed ID: 18635520
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant Streptococcus pneumoniae.
Zhanel GG; James J; Derkatch S; Laing N; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2006 Jul; 58(1):112-6. PubMed ID: 16644764
[TBL] [Abstract][Full Text] [Related]
33. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
Zinner SH; Vostrov SN; Alferova IV; Lubenko IY; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
[TBL] [Abstract][Full Text] [Related]
34. Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.
Pan AJ; Mei Q; Ye Y; Li HR; Liu B; Li JB
J Antibiot (Tokyo); 2017 Feb; 70(2):166-173. PubMed ID: 27756910
[TBL] [Abstract][Full Text] [Related]
35. Mutant prevention concentrations of pradofloxacin for susceptible and mutant strains of Escherichia coli with reduced fluoroquinolone susceptibility.
Marcusson LL; Komp Lindgren P; Olofsson SK; Hughes D; Cars O
Int J Antimicrob Agents; 2014 Oct; 44(4):354-7. PubMed ID: 25129317
[TBL] [Abstract][Full Text] [Related]
36. Mutant prevention concentration and phenotypic and molecular basis of fluoroquinolone resistance in clinical isolates and in vitro-selected mutants of Escherichia coli from dogs.
Gebru E; Damte D; Choi MJ; Lee SJ; Kim YH; Park SC
Vet Microbiol; 2012 Jan; 154(3-4):384-94. PubMed ID: 21893387
[TBL] [Abstract][Full Text] [Related]
37. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
38. The effect of the sub-minimal inhibitory concentration and the concentrations within resistant mutation window of ciprofloxacin on MIC, swimming motility and biofilm formation of Pseudomonas aeruginosa.
Shi N; Gao Y; Yin D; Song Y; Kang J; Li X; Zhang Z; Feng X; Duan J
Microb Pathog; 2019 Dec; 137():103765. PubMed ID: 31586475
[TBL] [Abstract][Full Text] [Related]
39. Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin.
Zinner SH; Golikova MV; Strukova EN; Portnoy YA; Firsov AA
Int J Antimicrob Agents; 2018 Dec; 52(6):854-860. PubMed ID: 30236953
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa.
Maciá MD; Borrell N; Segura M; Gómez C; Pérez JL; Oliver A
Antimicrob Agents Chemother; 2006 Mar; 50(3):975-83. PubMed ID: 16495260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
